Citius Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is October - September.

Millions USD. Fiscal year is Oct - Sep.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021
Selling, General & Admin	56.94	29.37	30.09	21.91	15.66	11.29
Research & Development	5.93	9.16	11.91	14.82	17.66	12.24
Operating Expenses	62.86	38.53	42	36.73	33.32	23.53
Operating Income	-57.37	-38.53	-42	-36.73	-33.32	-23.53
Interest Expense	-0.7	-0.27	-	-	-	-0.01
Interest & Investment Income	0.27	0.11	0.76	1.18	0.25	0.26
EBT Excluding Unusual Items	-57.8	-38.68	-41.24	-35.55	-33.06	-23.28
Gain (Loss) on Sale of Assets	3.83	-	2.39	3.59	-	-
Other Unusual Items	-	-	-	-	-	0.23
Pretax Income	-57.98	-38.68	-38.85	-31.97	-33.06	-23.05
Income Tax Expense	0.19	1.06	0.58	0.58	0.58	-
Earnings From Continuing Operations	-58.17	-39.74	-39.43	-32.54	-33.64	-23.05
Minority Interest in Earnings	11.89	2.31	0.29	-	-	-
Net Income	-46.27	-37.43	-39.14	-32.54	-33.64	-23.05
Preferred Dividends & Other Adjustments	-	-	1.05	1.15	-	1.45
Net Income to Common	-46.27	-37.43	-40.19	-33.69	-33.64	-24.51
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	22	11	7	6	6	4
Shares Outstanding (Diluted)	22	11	7	6	6	4
Shares Change	154.35%	64.49%	11.16%	3.57%	34.52%	177.28%
EPS (Basic)	-2.12	-3.38	-5.97	-5.57	-5.76	-5.64
EPS (Diluted)	-2.12	-3.38	-5.97	-5.57	-5.76	-5.64
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021
Free Cash Flow	-34.87	-26.55	-28.2	-29.06	-28.36	-24.26
Free Cash Flow Per Share	-1.60	-2.40	-4.19	-4.80	-4.85	-5.58
EBITDA	-	-38.52	-41.99	-36.73	-33.31	-23.53
D&A For EBITDA	-	0	0	0	0	0
EBIT	-57.37	-38.53	-42	-36.73	-33.32	-23.53

SEC Filings: 10-K · 10-Q